Landmark Bio, a contract development and manufacturing organization (CDMO) based in Watertown, Massachusetts, has secured up to USD 18.3 million in non-dilutive federal funding through the Advanced Research Projects Agency for Health (ARPA-H) TRANSFORM-EV program. The award will support development of a continuous manufacturing platform for extracellular vesicles (EVs) over a three-year period.
The funding was secured with support from EverGlade, a Houston-based advisory firm that assisted Landmark Bio through negotiations with ARPA-H, including multiple redesigns of the statement of work, milestones, and financial documentation. No private investors participated in this award. The TRANSFORM-EV program — formally titled Enabling Access to Transformative Therapies Through Continuous Manufacturing of Extracellular Vesicles — is directed at overcoming the low-yield, high-cost batch production methods that currently constrain clinical and commercial access to EV-based therapeutics.
Landmark Bio is an Artis BioSolutions company, having been acquired by Artis BioSolutions in April 2025. Prior to that acquisition, the company was established in 2021 through a founding consortium that included Harvard University, MIT, Cytiva, FUJIFILM Diosynth Biotechnologies, and Alexandria Real Estate Equities, alongside clinical partners such as Beth Israel Deaconess Medical Center, Boston Children's Hospital, Mass General Brigham, and Dana-Farber Cancer Institute. The ARPA-H award represents the largest single disclosed funding event in the company's history. Earlier non-dilutive support included a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), awarded in partnership with ChromaTan Inc. to develop intensified AAV production processes.